Celgene Presents Data on Revlimid and Rituxan in Follicular Lymphoma

Celgene International presented data this weekend at the American Society of Clinical Oncology's annual meeting in Chicago regarding a randomized study comparing Revlimid (lenalidomide) plus rituximab against lenalidomide monotherapy in previously treated patients with recurrent follicular lymphoma

45 patients were given either single-agent lenalidomide (15 mg in cycle 1 and 20 mg in cycles 2-12 administered on days 1-21 of each 28-day cycle) and 44 patients were given lenalidomide (15 mg in cycle 1 and 20 mg in cycles 2-12 administered on days 1-21 of each 28-day cycle) plus rituximab (375 mg/m2 weekly for four weeks in cycle 1).

Of the 89 evaluable patients, investigators noted an objective response rate of 73% in patients getting combination therapy (with 36% seeing complete response), compared to 51% for patients receiving the single-agent lenalidomide (with13% seeing a complete response).

With a median follow-up of 1.7 years (range 0.1 -- 4.1 years), the median event-free survival (EFS) for patients in the combination arm was 2 years. Patients in the single agent arm achieved a median EFS of 1.2 years.

While the data looks good, readers should keep in mind the small number of patients, as well as the fact that Revlimid not FDA-approved for the treatment of follicular lymphoma.

Source: MarketWatch

More Articles

More Articles

Mantle cell lymphoma (MCL) is a rare type of B-Cell lymphoma. It presents itself in the mantle zone of lymph nodes...

Large Cell Lymphoma (LCL) is typically an aggressive (fast growing) cancer of either the B cell or T cell type. They are one of the most common...

Indolent Lymphoma, or Indolent Non-Hodgkin’s Lymphomas (NHLs), are slow growing, low-grade cancers (as opposed to ...

A lymphoma prognosis varies greatly depending on the type of lymphoma. There are more than 35 types of lymphoma, including 5 types of...

Lymphomas are classified based on the type of cells involved. Non-Hodgkin’s lymphomas are marked by mutations of...

Hodgkin's Lymphoma (Disease) has a colorful history: It was not the first cancer discovered but it was one of the first in which treatments were...

There are two types of cancer: benign and malignant. Benign cancers are the kind that don't spread and don't threaten one's life. Malignant...

Cancer bracelets are undeniably popular, and if purchased through reliable sources such as major charities, they help contribute to the fight...

Hodgkin's Disease—also referred to as Hodgkin's Lymphoma, these are the exact same diseases, just...

Lymphoma is a cancer of the b- and t-cell lymphocytes, part of the immune system. They account for the most frequent head and neck malignancies....

Lymphoma is a cancer of the lymphatic system, causing B-cell or...

Lymphoma is a cancer affecting the white blood cells (lymphocytes) of the body's immune system. The cells begin to grow abnormally and much faster...

As a kind of cancer, lymphoma attacks the lymphocytes and lymph nodes that are part of the immune system. Head and neck lymphoma results when...

Some cancers have clear environmental causes. Oral cancer is strongly tied to the use of chewing tobacco, and lung cancer is well-known to be much...

The Follicular Lymphoma International Prognostic Index, or FLIPI, is a standardized guide to help oncological diagnosticians accurately calculate...